CITED2

Across TCGA pan-cancer cohorts, CITED2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CITED2 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CITED2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CITED2 expression acts as an unfavorable survival marker.

LIHC, CHOL, and GBM are the cancer types where CITED2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CITED2–LIHC (OS)

Open the LIHC breakdown →